RXi Pharmaceuticals (RXII) President and Chief Executive Officer to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Oct. 5, 2009 (GLOBE NEWSWIRE) -- What: RXi Pharmaceuticals Corporation (RXII) President and Chief Executive Officer will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Tod Woolf, President and Chief Executive Officer of RXi Pharmaceuticals Corp. (RXII), will preside over the NASDAQ Closing Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, October 6th 2009 at 3:45 p.m. to 4:00 p.m. ET Contacts: Donna Falcetti (508) 929-3615 ir@rxipharma.com NASDAQ MarketSite: Robert Madden (646) 441-5045 Robert.Madden@NASDAQOMX.com Feed Information: The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045. Radio Feed: An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well. Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/pages/NASDAQ-OMX/108167527653 For news tweets, please visit our Twitter page at: ...
Click here to read the whole Article (external link)

RXi Pharmaceuticals to Ring NASDAQ Stock Market Closing Bell

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII - News), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that Tod Woolf, Ph.D., President and CEO, along with members of RXi’s management team, will ring the Nasdaq closing bell tomorrow, Tuesday, Oct 6, 2009 at the Nasdaq Marketsite in New York City’s Times Square. Dr. Woolf’s brief remarks will recognize the progress RXi’s has made since trading began in March of 2008 and publicly thank all RXi shareholders for their continuing support.Webcast:A live webcast of the NASDAQ Closing Bell will be available at:http://www.nasdaq.com/about/marketsitetowervideo.asxAbout RXi Pharmaceuticals CorporationRXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA i...
Click here to read the whole Article (external link)

RXi Pharmaceuticals to Present Data Demonstrating the Robust Performance of its RNAi Therapeutics Platform at Upcoming Scientific Conference

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII - News), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Dmitry Samarsky, Ph.D., Vice President of Technology Development, will be presenting at the Discovery on Target scientific conference in Boston, MA tomorrow, November 4, 2009. The presentation will not be webcasted. The presentation will describe RXi’s therapeutic platform, including RXi’s next generation rxRNA™ compounds and advanced delivery approaches. The talk will focus on self-delivering rxRNA (sd-rxRNA™) compounds. Dr. Samarsky will present data exemplifying the robust performance of RXi’s self-delivering rxRNAs across multiple genes, cell types, target tissues and animal species.Craig Mello, Ph.D., Chairman of RXi’s Scientific Advisory Board and Noble Laureate noted, “The results presented by Dr. Samarsky demonstrate the robustness and potential for broad-based applications of self-delivering rxRNA to multiple therapeutic areas. Scientists are seeking RNAi-delivery solutions to disease tissues, and RXi’s results represent some of the most impressive delivery data in the field”.RXi is leveraging its therapeutic platform for both internal programs and external collaborations and partnerships to ...
Click here to read the whole Article (external link)

RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for RXI PHARMACEUTICALS CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for RXI PHARMACEUTICALS CORP 22-Oct-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational p...
Click here to read the whole Article (external link)

RXi Pharmaceuticals Appoints Noah D. Beerman as CEO

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII - News), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Noah D. Beerman has joined the company as its new President and Chief Executive Officer. The appointment of Mr. Beerman as CEO is part of a planned succession in leadership as the company looks to advance from the research stage to product development and execution of therapeutic collaborations and partnerships. He succeeds RXi’s co-founder, Tod Woolf, Ph.D., who will continue as a member of RXi’s Scientific Advisory Board (SAB). Mr. Beerman (47) joins RXi with over 25 years of experience in the biopharmaceutical industry and most recently served as Executive Vice President, Chief Business Officer for Indevus Pharmaceuticals, Inc., which was acquired by Endo Pharmaceuticals in March 2009 for $370 million plus future milestone payments. At Indevus, Mr. Beerman was responsible for the development and implementation of the company’s corporate development strategy to ensure near- and long-term growth and success. Noah was also responsible for overseeing Indevus’ acquisition of Valera Pharmaceuticals in 2007 and for managing the integration activities with Endo as part of this transaction.Prior to joining Indevus in 1997, Mr. Beerman wa...
Click here to read the whole Article (external link)

RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2009

RXi Pharmaceuticals Corporation (A Development Stage Company)   Condensed Statements of Expenses (in thousands, except share and per share data) (Unaudited)         For the Three Months Ended For the Three Months Ended For the Nine Months Ended For the Nine Months Ended September 30, September 30, September 30, September 30, 2009 2008 2009 2008 Research and development expense $ 2,091 $ 1,200 $ 6,533 ...
Click here to read the whole Article (external link)

RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) As part of a plan succession in leadership, Tod Woolf, Ph.D., resigned as President, Chief Executive Officer and a member of the Board of Directors (the "Board") of RXi Pharmaceuticals Corporation, effective November 5, 2009. Dr. Woolf's decision to resign was not a result of any disagreement with the Company or its management. Dr. Woolf will remain with the Company as a member of its scientific advisory board. (c) On November 5, 2009, the Board appointed Noah D. Beerman as its President and Chief Executive Officer, effective immediately. Mr. Beerman, age 47, has over 25 years of experience in the biopharmaceutical industry. From 1997 until April 2009, Mr. Beerman held a variety of leadership positions, most recently serving as Executive Vice President and Chief Business Officer at Indevus Pharmaceuticals, Inc., which was acquired by Endo Pharmaceuticals in March 2009. Prior to joining Indevus, Mr. Beerman was responsible for health care as vice president at Technology Management and Funding ("TMF"), a venture firm where he developed and executed business and commercialization strategies for TMF's biotechnology portfolio. Earlier in his career, he served in a variety of business and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen. Mr. Beerman holds an M.B.A. from Northeastern University's High Technology Program and a B.S. in molecular genetics from the University of Rochester. Mr. Beerman does not have a family relationship with any existing member of the Board or any executive officer of the Company. Under the terms of Mr. Beerman's employment agreement (the "Agreement"), the Company is obligated to appoint him to the Board promptly following the effective date of the Agreement. Mr. Beerman is also entitled to a sign-on bonus of $25,000, options to purchase 350,000 sha...
Click here to read the whole Article (external link)

RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for RXI PHARMACEUTICALS CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for RXI PHARMACEUTICALS CORP 17-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for information...
Click here to read the whole Article (external link)

RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS In this document, "we," "our," "ours" and "us" refer to RXi Pharmaceuticals Corporation This management's discussion and analysis of financial condition as of September 30, 2009 and results of operations for the three and nine months ended September 30, 2009 and 2008 should be read in conjunction with management's discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2008. The discussion and analysis below includes certain forward-looking statements related to future operating losses and our potential for profitability, the sufficiency of our cash resources, our ability to obtain additional equity or debt financing, possible partnering or other strategic opportunities for the development of our products, as well as other statements related to the progress and timing of product development, present or future licensing, collaborative or financing arrangements or that otherwise relate to future periods, which are all forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements represent, among other things, the expectations, beliefs, plans and objectives of management and/or assumptions underlying or judgments concerning the future financial performance and other matters discussed in this document. The words "may," "will," "should," "plan," "believe," "estimate," "intend," "anticipate," "project," and "expect" and similar expressions are intended to identify forward-looking statements. All forward-looking statements involve certain risks, uncertainties and other factors described elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2008, that could cause our actual results of operati...
Click here to read the whole Article (external link)